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Abstract
Purpose Ligand-dependent corepressor (LCoR) and receptor-interacting protein 140 (RIP140/NRIP1) play an important 
role in the regulation of multiple oncogenic signaling pathways and the development of cancer. LCoR and RIP140 form a 
nuclear complex in breast cancer cells and are of prognostic value in further prostate and cervical cancer. The purpose of 
this study was to analyze the regulation of these proteins in the development of cervical intraepithelial neoplasia (CIN I–III).
Methods Immunohistochemical analysis was obtained to quantify RIP140 and LCoR expression in formalin-fixed paraffin 
embedded tissue sections of cervical intraepithelial neoplasia samples. Tissue (n = 94) was collected from patients treated 
in the Department of Gynecology and Obstetrics, Ludwig-Maximilians-University of Munich, Germany, between 2002 and 
2014. Correlations of expression levels with clinical outcome were carried out to assess for prognostic relevance in patients 
with CIN2 progression. Kruskal–Wallis test and Mann–Whitney U test were used for data analysis.
Results Nuclear LCoR overexpression correlates significantly with CIN II progression. Nuclear RIP140 expression signifi-
cantly increases and nuclear LCoR expression decreases with higher grading of cervical intraepithelial neoplasia. Cytoplas-
mic RIP140 expression is significantly higher in CIN III than in CIN I or CIN II.
Conclusion A decrease of nuclear LCoR expression in line with an increase of dedifferentiation of CIN can be observed. 
Nuclear LCoR overexpression correlates with CIN II progression indicating a prognostic value of LCoR in cervical intraepi-
thelial neoplasia. Nuclear and cytoplasmic RIP140 expression increases significantly with higher grading of cervical intraepi-
thelial neoplasia underlining its potential role in the development of pre-cancerous lesions. These findings support the 
relevance of LCoR and RIP140 in the tumorigenesis indicating a possible role of LCoR and RIP140 as targets for novel 
therapeutic approaches in cervical intraepithelial neoplasia and cervical cancer.
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Abbreviations
CIN  Cervical intraepithelial neoplasia
LCoR  Ligand-dependent corepressor
RIP140  Receptor-interacting protein of 140 kDa
NRIP1  Nuclear receptor-interacting protein 1 
(= RIP140)
Erα  Estrogen receptor α
KLF6  Krüppel-like factor 6
pRb  Retinoblastoma protein
OS  Overall survival
Introduction
Cervical cancer is the fourth most common cancer in 
females worldwide with more than 500,000 new cases 
each year (World Health Organization 2019, January 24). 
Furthermore, it is causing 7.5% of all cancer deaths in 
women (Ferlay et al. 2019). Due to routine cervical cancer 
screening methods such as HPV testing and cervical cytol-
ogy (i.e. Pap smear test), the incidence of cervical cancer 
has decreased strongly, implicating the importance of the 
detection and treatment of pre-cancerous lesions, cervical 
intraepithelial neoplasia (CIN) (Schiffman and Wentzensen 
2013). CINs are categorized into three grades (CIN I–III) 
depending on the amount of dysplastic epithelium involved. 
The major leading cause for the development of CIN and 
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ultimately invasive cancer is a persistent infection with high-
risk Human Papillomavirus (HR-HPV) (Schiffman et al. 
2011). When expressed, the viral oncoprotein E6 disturbs 
the cell cycle by binding and degrading the tumor suppres-
sor protein p53 (Gupta et al. 2003; Scheffner et al. 1990). 
The viral oncoprotein E7 disturbs the cell cycle by binding 
and degrading the retinoblastoma protein (pRb) and trig-
gering E2F dissociation leading to proliferation of the cell 
and inhibition of cell death and differentiation (Chellappan 
et al. 1992; Wise-Draper and Wells 2008).
In the last 5–9 years, incidence of cervical intraepithelial 
neoplasia grades II and III has decreased by 30–50% due 
to HPV vaccination while incidence of CIN II and III has 
increased significantly by 19–23% in patients without HPV 
vaccination (Drolet et al. 2019).
Ligand dependent corepressor (LCoR) was initially 
described as a coregulator of estrogen receptor α (ERα) 
(Fernandes et al. 2003). Recent studies suggest its interac-
tion with various transcription factors such as Krüppel-like 
factor 6 (KLF6) (Calderon et al. 2012) and peroxisome 
proliferator-activated receptor γ (PPARγ) (Shalom-Barak 
et al. 2018). It acts by recruiting histone deacetylases and 
C-terminal binding proteins (Palijan et al. 2009a, b). Asim 
and colleagues could show that LCoR inhibits prostate can-
cer growth in a xenograft mouse model via co-repression of 
activated androgen receptor (AR) (Asim et al. 2011).
Receptor-interacting protein of 140 kDa (RIP140), also 
known as nuclear receptor-interacting protein 1 (NRIP1), 
is described as a transcriptional coregulator of agonist-
liganded ERα. Similar to LCoR, it functions by recruiting 
histone deacetylases and C-terminal binding proteins (Castet 
et al. 2004; Christian et al. 2004). RIP140 acts mostly as 
a co-repressor of multiple nuclear receptors and transcrip-
tion factors and limits their transactivation (Augereau et al. 
2006a, b; Cavailles et al. 1995).
RIP140 plays an important role in the progression and 
development of cancer (Aziz et al. 2015; Ghoussaini et al. 
2012; Lapierre et al. 2014, 2015; Lei et al. 2015). In colon 
cancer, RIP140 is involved in Wnt-signaling and has a 
negative effect on Wnt/β-Catenin target genes and thereby 
inhibits cell proliferation, epithelial cell progression, and 
tumor growth (Lapierre et al. 2014, 2015). Direct interaction 
between RIP140 and E2F1 in breast cancer cell lines results 
in a repression of E2F1 target genes and could regulate cell 
proliferation (Docquier et al. 2010). Furthermore, RIP140 is 
essential for repressive activity of LCoR in breast cancer cell 
proliferation. LCoR overexpression and parallel downregula-
tion of RIP140 mRNA leads to an increase in cell prolifera-
tion in breast cancer cell lines (Jalaguier et al. 2017). Low 
LCoR and RIP140 gene expression levels were associated 
with shorter overall survival (OS) in patients diagnosed with 
breast cancer (Jalaguier et al. 2017). Conversely, in a recent 
study we showed that RIP140 overexpression was associated 
with significant shorter overall survival of cervical cancer 
patients. RIP140 is not a significant negative prognosticator 
if LCoR expression is low (Vattai et al. 2017).
RIP140 and LCoR recruit similar cofactors implicated 
in transcriptional co-repression suggesting many paral-
lels in their mechanism of action (White et al. 2004). Both 
RIP140 and LCoR bind to agonist-bound ligand binding 
domains (LBD), blocking coactivation in vivo (White et al. 
2004). Multiple function and structure studies have dis-
played that RIP140 and LCoR recognize the same coac-
tivator binding pockets of nuclear receptor LBDs (White 
et al. 2004).
Aim of this study was to analyze the expression of LCoR 
and RIP140 in cervical intraepithelial neoplasia grade I, II 
and III (CIN I–III) and the correlation of their expression 
regarding the progression of cervical dysplasia.
Methods
Formalin-fixed paraffin embedded samples of 94 patients 
who had been treated at the Department of Gynecology and 
Obstetrics at Ludwig-Maximilians-University Munich, Ger-
many, between 2002 and 2014 were included in this study. 
81 slides could be obtained for analysis and 13 slides were 
not considered for analysis due to failed staining or no CIN 
staining on the slide. Patients were either diagnosed with 
CIN I (n = 38), CIN II (n = 26) or CIN III (n = 17). There 
has been no preselection of the patients. Histopathologi-
cal grade of dysplasia and diagnosis were confirmed by a 
second gynecological pathologist. For progression analy-
sis in CIN II samples, only patients with a follow-up visit 
and a histologically confirmed regress (n = 7) or progress 
(n = 17) were included. On their first visit all patients were 
tested positive for high risk Human Papillomavirus (Hybrid 
Capture 2, Quiagen). Initially, the tissue analyzed in this 
study had been collected due to routine histopathological 
diagnostics. All diagnostic procedures had been carried out 
beforehand.
Immunohistochemistry
Immunohistochemical quantification of LCoR and RIP140 
expression was obtained in the embedded samples of cer-
vical dysplasia (CIN I–III). Immunohistochemical staining 
was obtained as described in earlier publications (Hester 
et al. 2019; Vattai et al. 2017). Tissue samples were surgi-
cally generated and instantly fixed in neutral buffered for-
malin (3.7%) followed by standardized paraffin bedding. 
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Immunohistochemistry was initiated by deparaffiniza-
tion of the formalin-fixed paraffin embedded tissue slices 
(3 µm) in xylol. Inactivation of endogenous peroxidase 
was obtained with 3%  H2O2 in methanol for 20 min fol-
lowed by a descending ethanol gradient for rehydration 
of the slides. Next, a pressure cooker filled with sodium 
citrate buffer (pH 6.0) was used to prepare the tissue for 
epitope retrieval. To prevent non-specific binding of the 
primary antibodies, blocking solution was applied. The 
tissue slides were incubated over night for 16 h consecu-
tively with the following antibodies: anti-LCoR (poly-
clonal rabbit IgG, Novus Biologicals, Littleton, USA) 
and anti-RIP140 (polyclonal rabbit IgG, Sigma Aldrich, 
St. Louis, USA). Analyzation of the antibody reactivity 
was obtained with the ZytoChemPlus HRP Polymer Sys-
tem (mouse/rabbit) (Zytomed Systems, Berlin, Germany) 
according to the manufacturer’s protocol. Substrate and 
chromogen (3,3′-diaminobenzidine DAB; Dako, Glostrup, 
Denmark) was applied on the samples. Counterstaining 
was obtained with Mayer’s acidic hematoxylin. After 
dehydrating the slides in an ascending row of ethanol, the 
slides were cover slipped. Both nuclear and cytoplasmic 
staining of LCoR and RIP140 were further correlated with 
EP3 staining which has been carried out and published 
previously (Hester et al. 2019).
Quantification
Analyzation of cervical dysplasia tissues was conducted by 
two different and independent observers using Leitz Dia-
plan microscope (Leitz, Wetzlar, Germany). To quantify 
each slide’s staining, the semiquantitative immunoreactive 
score (IRS) was used. Intensity and distribution pattern of 
the antigen are optically evaluated with the immunoreactive 
score (IRS) (Remmele and Stegner 1987). It was calculated 
by multiplying staining intensity (0: none; 1: weak; 2: mod-
erate; 3: strong) with the number of positively stained cells 
(in %) (0: no staining, 1: < 10% of the cells; 2: 11–50%; 3: 
51–80%; 4: > 80%). A scale from 0 (no expression) to 12 
(very high expression) was used. Photos were taken with a 
CCD color camera (JVC, Victor Company of Japan, Japan).
Statistical analysis
For data analysis IBM SPSS Statistics for Windows, Version 
25, was used. P values p < 0.05 were considered statistically 
significant. Comparative analysis between different grades 
of CIN was obtained using nonparametric Kruskal–Wallis 
rank-sum test and Mann–Whitney U test. Spearman’s rank 
correlation coefficient was used for correlation analysis. Fig-
ures were designed using IBM SPSS Statistics for Windows, 
Version 25 as well as Microsoft® PowerPoint for Mac Ver-
sion 16.30 (19101301).
Results
Nuclear LCoR expression in CIN grade I–III 
and correlation analysis with histopathological 
variables
Differences in nuclear LCoR expression were examined by 
comparing LCoR immunoreactive scores (IRS) between the 
groups of cervical tissue as shown in Fig. 1. While CIN I and 
CIN II showed a median IRS of four, median IRS in CIN III 
was two (p = 0.008). LCoR expression compared between 
CIN I and CIN II is not significantly changed (p = 0.088). 
Exemplary staining for all CIN grades is shown in Fig. 1.
For positive nuclear LCoR expression in cervical dyspla-
sia tissue, a significant correlation with cytoplasmic LCoR 
(p = 0.014, Spearman Rho 0.270) was detected. Cytoplasmic 
RIP140 expression was negatively correlated with nuclear 
LCoR expression (p = 0.043; Spearman Rho − 0.224).
RIP140 expression in CIN grade I–III
RIP140 expression was observed in the nucleus as well as the 
cytoplasm. In both compartments RIP140 expression signifi-
cantly increased with higher grading of dysplasia as shown 
in Figs. 2 and 3. While CIN I showed a nuclear RIP140 
expression with a median of two, the median in CIN II was 
five and in CIN III the median IRS was six (Kruskal–Wallis 
test p = 0.000). Cytoplasmic RIP140 expression in CIN I and 
CIN II with a median of zero increased significantly to the 
median of one in CIN III (Kruskal–Wallis test p = 0.001). 
Exemplary staining for all grades of CIN is shown in Figs. 2 
and 3.
Correlation analysis showed that nuclear RIP140 
expression correlated positively with cytoplasmic RIP140 
(p = 0.000; Spearman Rho 0.552). Nuclear RIP140 cor-
related negatively with EP3 expression (p = 0.010; Spear-
man Rho − 0.290) in cervical dysplasia tissue. Cytoplasmic 
RIP140 expression correlated negatively with EP3 expres-
sion (p = 0.001, Spearman Rho − 0.365).
Nuclear LCoR expression and progression of CIN
We compared nuclear LCoR expression between CIN II 
cases with histologically confirmed progress or regress to 
evaluate if LCoR expression is a prognostic marker for a 
progressive or regressive course in CIN. The median IRS of 
CIN II that showed a regressive course was three whereas 
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the median IRS of CIN II with a progressive course was six 
(Fig. 4, Kruskal–Wallis test p = 0.004).
Discussion
In a previous study we could show that patients with cervical 
cancer expressing low levels of LCoR and RIP140 correlate 
with a better overall survival than patients expressing high 
levels of RIP140 (Vattai et al. 2017). RIP140 is an independ-
ent predictor of poor OS in patients with cervical cancer 
(Vattai et al. 2017). In the current study we could show that 
nuclear RIP140 expression increases significantly with the 
cervical dysplasia grade. In line with our findings, RIP140 
plays a role in different molecular pathways that affect the 
development of cervical cancer such as the estrogen recep-
tor signaling (Lapierre et al. 2015). Elevated estrogen levels 
lead to a higher risk of cervical intraepithelial neoplasia as 
well as cervical cancer in HPV-infected patients (Ramachan-
dran 2017).
Besides its influence on estrogen receptor signaling, 
RIP140 represses transactivation of E2F1 and inhibits 
expression of several E2F1 target genes in breast cancer 
cell lines (Docquier et al. 2010). E2F1 is a transcriptional 
activator that plays an essential role in the regulation of cell 
proliferation, apoptosis, G1/S transition and S-phase entry 
during the cell cycle (Chen et al. 2009; Dimova and Dyson 
2005). It can bind to and is regulated by the tumor suppres-
sor protein retinoblastoma (pRb) (McNair et al. 2018). Phos-
phorylation of pRb by G2-M and S-phase cyclin dependent 
kinases releases E2F1 and allows it to transcribe its target 
genes resulting in cell cycle progression (Weinberg 1995). 
The degradation of E2F repressor pRb by the HPV onco-
protein E7 via the ubiquitin–proteasome pathway results in 
activation of E2F-regulated genes and consequently deregu-
lates the progression through the G1 phase of the cell cycle 
(Boyer et al. 1996; Rosty et al. 2005). In cervical cancer, 
E2F1 expression is significantly increased suggesting that 
genes which are involved in invasive cervical carcinoma are 
regulated by E2F (Rosty et al. 2005; Srivastava et al. 2014).
Fig. 1  Correlation of nuclear LCoR expression (IRS) with grade 
of dysplasia. a Boxplot of nuclear LCoR expression and grade of 
dysplasia. b CIN I (n = 37) with nuclear LCoR IRS of 4; magnifi-
cation × 10. c CIN II (n = 26) with nuclear LCoR IRS of 3; magni-
fication × 10. d CIN III (n = 16) with nuclear LCoR IRS of 2; magni-
fication × 10
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Another pathway influenced by RIP140 is Wnt/β-catenin 
signaling which is involved in cancer progression. Lapierre 
et al. (2014) showed a suppressive effect of RIP140 on 
Wnt/β-catenin target genes in colon cancer. This stands in 
contrast to the previously described role of RIP140 in cer-
vical and breast cancer and to our results in CIN indicating 
the complexity of RIP140 regulation (Aziz et al. 2015; Vat-
tai et al. 2017). The Wnt/β-catenin signaling pathway has 
been described in HPV-related tumors implicating potential 
mechanisms by which the viral oncoproteins E6 and E7 acti-
vate this pathway (Bello et al. 2015).
In CIN III, cytoplasmic RIP140 expression is signifi-
cantly higher than in CIN I or CIN II. Nucleo-cytoplasmic 
shuttling or a higher transcription followed by modification 
of RIP140 might explain the cytoplasmic increase. After 
transcription of genes in the nucleus, proteins are transported 
to the cytoplasm for translation and modification (Fu et al. 
2018). For shuttling, nuclear pore complexes (NPCs) selec-
tively transport cargoes across the nuclear envelope (Alber 
et al. 2007). Nucleo-cytoplasmic shuttling plays an impor-
tant role in activity of proteins, signaling pathways, and 
thereby tumorigenesis (Shreberk-Shaked and Oren 2019). 
Post-translational modifications such as lysine acetylation 
(Vo et al. 2001) or conjugation to Vitamin-B6 (Huq et al. 
2007) might play a role in nucleo-cytoplasmic shuttling.
LCoR is described as a tumor suppressor in prostate 
cancer and an inhibitor of cell growth in prostatic cancer 
cells (Asim et al. 2011). In breast cancer cell lines, LCoR 
is regulated by RIP140 and inhibits cell proliferation. 
Jalaguier and colleagues (2017) could show that LCoR 
mRNA is expressed higher in breast cancer cell lines than 
in normal samples. In this study, we could show that high 
nuclear LCoR expression correlates significantly with CIN 
II progression. High LCoR expression might thereby lead 
to a higher grade of dysplasia and towards tumorigenesis. 
Interestingly, high LCoR expression furthermore correlates 
significantly with low dysplasia grade. In general, 50% of 
histologically confirmed CIN II lesions show a regressive 
Fig. 2  Correlation of nuclear RIP140 expression (IRS) with grade 
of dysplasia. a Boxplot of nuclear RIP140 expression and grade of 
dysplasia. b CIN I (n = 38) with nuclear RIP140 IRS of 1; magnifica-
tion × 10. c CIN II (n = 26) with nuclear RIP140 IRS of six; magnifi-
cation × 10. d CIN III (n = 17) with nuclear RIP140 IRS of six; mag-
nification × 10
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course while only 18% progress to CIN III or worse within 
2 years of surveillance (Tainio et al. 2018). Cervical dys-
plasia is common in young women and it has been contro-
versially discussed whether or not CIN II is an indication 
for surgical treatment since loop electrosurgical excision 
procedure (LEEP) is associated with a significant higher 
risk of premature birth in following pregnancies (Frega 
et al. 2018). Therefore, it is of high importance to differ-
entiate between a potentially progressive and regressive 
CIN II.
Correlations of LCoR and RIP140 expression have been 
described in studies on breast, cervical, and gastrointesti-
nal cancer (Jalaguier et al. 2017; Triki et al. 2017; Vattai 
et al. 2017). In our study, we detected a negative correlation 
between nuclear LCoR and cytoplasmic RIP140 expres-
sion (p = 0.005). Correlation of nuclear RIP140 and nuclear 
LCoR expression was not significant.
In conclusion, in our hypothesis generating study we 
observed that RIP140 as well as LCoR are expressed differ-
ently in all grades of cervical intraepithelial neoplasia, with 
the exception of LCoR expression compared between CIN 
I and CIN II, suggesting that LCoR and RIP140 play a rel-
evant role in carcinogenesis of cervical cancer. Additionally, 
LCoR expression appears to be a marker for CIN II progres-
sion. Further experiments are required to analyze whether 
LCoR can be considered as an additional diagnostic factor to 
help in the decision-making process regarding non-surgical 
treatment eligibility of CIN II patients.
Fig. 3  Correlation of cytoplasmic RIP140 expression (IRS) with 
grade of dysplasia. a Boxplot of cytoplasmic RIP140 expression and 
grade of dysplasia. b CIN I (n = 38) with cytoplasmic RIP140 IRS 
of 0; magnification × 25. c CIN II (n = 26) with cytoplasmic RIP140 
IRS of zero; magnification × 10. d CIN III (n = 17) with cytoplasmic 
RIP140 IRS of two; magnification × 10
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